Simplify diabetes management for your patients
Omnipod® 5 Automated Insulin Delivery
- SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to your personal needs which may help to protect against highs and lows.1
- The first wearable, tubeless, hybrid closed loop system that integrates with the leading sensor brands, for your patients with type 1 diabetes (T1D) aged 2 years and older.‡
- Improved glycaemic control and improved patient-reported outcomes including improved sleep quality vs prior therapy in parents of children from 6 years†1,2,4
The System - 3 Simple Parts
Controller + Pod + Sensor
The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to your personal needs which may help to prevent against highs and lows*. Watch this video to learn more.
Want to get a hands-on understanding of our intuitive Omnipod 5 AID system?
Try the free simulator app on your smartphone.
We believe in freedom of choice
For people with type 1 diabetes, we know that choosing an insulin pump for the first time or changing from an existing one is not an easy option.
We are also aware that four-year warranties on insulin pumps are typically viewed as ‘lock-in’ periods and a potential barrier to patient choice.
That why we strive to take steps to facilitate flexibility and reduce ‘lock-in’ periods with the Omnipod DASH® and Omnipod® 5 System.
The actual steps we take may vary by location, to understand more on how we do this; contact your local Omnipod® Representative or request a call-back.
The Omnipod DASH® System
Help your patients manage T1D with an easy-to-use insulin delivery system and support them in improving glycaemic control.*3
View this short video to find out more about Pod Therapy and learn how the Omnipod DASH® Insulin Management System could benefit your patients.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod.
† Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
‡ The first AID system to be CE marked that is integrated with the Dexcom G6 sensor or the Freestyle Libre 2 Plus sensor.
1.Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM.
2.Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM.
3. Aleppo G et al. Diabetes Ther. (2023). Retrospective observational study of 4,738 people with T1D in the US before (baseline) and 90 days after (follow-up) initiation of the tubeless Omnipod DASH Insulin Management System, children, adolescents and adults who switched from MDI to Omnipod saw an improvement in HbA1c of -0.9% (8.6 to 7.7% for pediatric participants and 8.5% to 7.6% for adults); Pediatric self-reported hypoglycemia episodes/week improved - 1.3 (2.8 to 1.5) and adult hypoglycemia improved - 1.6 (2.9 to 1.3). All results had p-value <0.0001.
4. Hood KK, et al. Pediatric Diabetes (2023). Study in children with type 1 diabetes and their caregivers (n=82) involving 2 weeks standard therapy followed by 3 months of Omnipod 5 use in Automated Mode. Sleep quality measured by Pittsburgh Sleep Quality Index (PSQI). No difference in PSQI total score. Difference in overall sleep quality subset score in caregivers 1.12 vs. 0.70 (P<0.0001) respectively.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog®, Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Admelog/Insulin lispro Sanofi U-100 insulin.
Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.
Refer to Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.